Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors

To join this study, you need to be 18 years or older and generally well enough to take part in daily activities. Doctors will check if your main cancer area is under control and that you have between 4 and 10 small areas where the cancer has spread. All these small cancer spots must be in places that can be safely treated with the special radiation.

You wouldn't be able to join if you have serious health problems that might make radiation treatment unsafe, such as certain lung or gut conditions. Also, if you have a very large single cancer spot (over 5 cm) or significant spread to certain areas like the brainstem or extensive brain involvement, you wouldn't be suitable. Women who are pregnant or breastfeeding also cannot participate.

This study is a 'Phase 3' trial, which means it's comparing a new approach (SABR) with standard treatments to see which is better. You would be randomly assigned to either receive SABR or continue with standard treatments like chemotherapy, immunotherapy, hormone therapy, or watchful waiting, as decided by your doctors. The specific duration of your treatment and follow-up would depend on which group you are in and your individual treatment plan. You would have regular check-ups, scans, and discussions with the study team to monitor your progress and well-being. The total duration of follow-up for the study will likely be several years to assess long-term outcomes, but the most intensive parts involving active treatment would be shorter.